11 completed, 2 unknown, 1 enrolling by invitation, 1 recruiting. 6 Not applicable, 6 Phase 4, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 6 | Completed 5, Unknown 1 |
| Phase 4 | 6 | Completed 2, Enrolling by invitation 1, Recruiting 1, Suspended 1, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Fosinopril: new trials by email Literature Review of Fosinopril trials Research Report on Fosinopril
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Coronavirus (COVID-19) ACEi/ARB Investigation Thiazide or Thiazide-like diuretics, Calcium Channel Blockers, ACE inhibitor - Hypertension, COVID-19 | Phase 4 | Suspended | National University of Ireland, Galway, Ireland | 2414 | 2020-04-30 | 2020-06-30 |
| ACEI or ARB and COVID-19 Severity and Mortality in US Veterans ACEI/ARB, Non-ACEI/ARB, ACEI - Hypertension, COVID | Completed | University of Utah | 22213 | 2020-01-19 | 2021-04-28 | |
| NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients RAS-antagonist and beta-blocker up-to maximal dosages, RAS-antagonist and beta-blocker none or at stable dose - Heart Diseases, Diabetes Mellitus, Type 2 | Phase 4 | Recruiting | Martin Huelsmann | 2400 | 2016-02-01 | 2023-03-14 |
| Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension Fosinopril, Benidipine, Hydrochlorothiazide - Chronic Kidney Disease | Phase 4 | Unknown | Shanghai Changzheng Hospital | 508 | 2016-02-01 | 2016-01-05 |
| Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery ACEI continuation, ACEI omission - Hypotension on Induction | Phase 4 | Completed | University of Nebraska | 291 | 2015-06-01 | 2023-09-25 |
| Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD) Fosinopril, lactose - Chronic Obstructive Pulmonary Disease | Phase 4 | Completed | Imperial College London | 80 | 2009-10-01 | 2015-03-25 |
| Eplerenone, ACE Inhibition and Albuminuria eplerenone, fosinopril, placebo - Diabetic Nephropathy | Phase 2 | Completed | Radboud University Medical Center | 30 | 2007-01-01 | 2012-05-28 |
| The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension Fosinopril, Metformin - Diabetes Mellitus, Essential Hypertension | Not applicable | Completed | China-Japan Friendship Hospital | 140 | 2006-05-01 | 2011-05-13 |
| Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3 Fosinopril and Losartan - Chronic Kidney Insufficiency, Angiotensin-Converting Enzyme Inhibitors | Not applicable | Unknown | Shanghai Municipal Health Bureau | 400 | 2004-09-01 | 2007-11-30 |
| Bioequivalence Study of Fosinopril Sodium/ Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fasting Conditions Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets - Healthy | Not applicable | Completed | Ranbaxy Laboratories Limited | 34 | 2003-03-01 | 2008-10-23 |
| Bioequivalence Study of Fosinopril Sodium / Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fed Conditions Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets - Healthy | Not applicable | Completed | Ranbaxy Laboratories Limited | 33 | 2003-03-01 | 2008-10-23 |
| Bioequivalence Study of Fosinopril 40mg Tablets Under Fed Conditions Fosinopril 40mg Tablets - Healthy | Not applicable | Completed | Ranbaxy Laboratories Limited | 24 | 2002-10-01 | 2008-10-21 |
| Bioequivalence Study of Fosinopril 40mg Tablets Under Fasting Conditions Fosinopril 40mg Tablets - Healthy | Not applicable | Completed | Ranbaxy Laboratories Limited | 40 | 2002-10-01 | 2008-10-21 |
| ACE Inhibition and Novel Cardiovascular Risk Factors Fosinopril - Cardiovascular Diseases, Heart Diseases | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 2002-02-01 | 2016-02-18 | |
| Prevention of Renal and Vascular Endstage Disease Intervention Trial Fosinopril, Pravastatin, Fosinopril Placebo - Microalbuminuria, Cardiovascular Diseases | Phase 3 | Completed | University Medical Center Groningen | 864 | 1998-04-01 | 2017-03-10 |
Hypertension (5) · Cardiovascular Diseases (3) · Renal Insufficiency, Chronic (3) · Albuminuria (2) · Diabetes Mellitus, Type 2 (2) · Heart Diseases (2) · COVID-19 (1) · Coronavirus Infections (1) · Diabetes Mellitus (1) · Diabetic Nephropathies (1) · Essential Hypertension (1) · Hyperinsulinism (1) · Hyperkalemia (1) · Insulin Resistance (1) · Kidney Diseases (1)
Ranbaxy Laboratories Limited (4) · Baylor Research Institute (1) · China-Japan Friendship Hospital (1) · Imperial College London (1) · Martin Huelsmann (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · National University of Ireland, Galway, Ireland (1) · Radboud University Medical Center (1) · Shanghai Changzheng Hospital (1) · Shanghai Municipal Health Bureau (1) · University Medical Center Groningen (1) · University of Nebraska (1) · University of Utah (1)
United States (7) · China (2) · Netherlands (2) · United Kingdom (2) · Austria (1) · Ireland (1) · New Zealand (1) · Spain (1)
Adam P Bress, PharmD, MS (1) · Changlin Mei (1) · Jacob Deinum, MD (1) · Jason F Shiffermiller, MD, MPH (1) · John William McEvoy, MBBCh MHS (1) · Marco Pahor (1) · Martin Huelsmann, Doz.Dr. (1) · Nan Chen, M.D. (1) · Nicholas S Hopkinson, MRCP, PhD (1) · Wiek H van Gilst, PhD (1)
PMID 28237959, PMID 29237679, PMID 30261084, PMID 33107592, PMID 33891615
R01HL068901 (1)